1. Home
  2. RYM vs CNTB Comparison

RYM vs CNTB Comparison

Compare RYM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYM
  • CNTB
  • Stock Information
  • Founded
  • RYM 2016
  • CNTB 2012
  • Country
  • RYM United States
  • CNTB United States
  • Employees
  • RYM N/A
  • CNTB N/A
  • Industry
  • RYM Farming/Seeds/Milling
  • CNTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • RYM Consumer Staples
  • CNTB Health Care
  • Exchange
  • RYM Nasdaq
  • CNTB Nasdaq
  • Market Cap
  • RYM 85.7M
  • CNTB 90.3M
  • IPO Year
  • RYM 2021
  • CNTB 2021
  • Fundamental
  • Price
  • RYM $42.91
  • CNTB $1.49
  • Analyst Decision
  • RYM
  • CNTB Strong Buy
  • Analyst Count
  • RYM 0
  • CNTB 2
  • Target Price
  • RYM N/A
  • CNTB $7.50
  • AVG Volume (30 Days)
  • RYM 14.4K
  • CNTB 91.2K
  • Earning Date
  • RYM 11-13-2025
  • CNTB 09-05-2025
  • Dividend Yield
  • RYM N/A
  • CNTB N/A
  • EPS Growth
  • RYM N/A
  • CNTB N/A
  • EPS
  • RYM N/A
  • CNTB N/A
  • Revenue
  • RYM $12,260,000.00
  • CNTB $1,965,000.00
  • Revenue This Year
  • RYM N/A
  • CNTB N/A
  • Revenue Next Year
  • RYM N/A
  • CNTB $453,067.90
  • P/E Ratio
  • RYM N/A
  • CNTB N/A
  • Revenue Growth
  • RYM 186.99
  • CNTB N/A
  • 52 Week Low
  • RYM $2.71
  • CNTB $1.23
  • 52 Week High
  • RYM $84.44
  • CNTB $2.20
  • Technical
  • Relative Strength Index (RSI)
  • RYM N/A
  • CNTB 43.73
  • Support Level
  • RYM N/A
  • CNTB $1.36
  • Resistance Level
  • RYM N/A
  • CNTB $1.58
  • Average True Range (ATR)
  • RYM 0.00
  • CNTB 0.14
  • MACD
  • RYM 0.00
  • CNTB -0.01
  • Stochastic Oscillator
  • RYM 0.00
  • CNTB 46.43

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Share on Social Networks: